Process and quality considerations for recombinant adeno-associated virus manufacturing platforms
Trends in Biotechnology · 2025-08 · 43 (8) · 1921-1937
DOI: 10.1016/j.tibtech.2025.02.016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2025-08. Verfasst von Min Tae Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: BioProcess Sciences, Pharma Services, Viral Vector Services, Thermo Fisher Scientific, Plainville, MA 02762, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Vectors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Recombinant adeno-associated virus (AAV) is a prominent gene therapy vector, offering a strong safety profile and sustained gene expression. Scaling up AAV manufacturing remains challenging due to its complex processes, high development costs, and the need for rigorous quality control. This review examines the most common AAV suspension production platforms, specifically transfection, infection, and stable producer cell lines (PCLs). For each platform, a list of common unit operations and typical ranges for critical operating parameters is provided, along with high-level product quality specifications. This review aims to offer insights into the advantages and challenges of each manufacturing platform, providing a framework for accelerated process development and informed selection of suitable production platform based on intended clinical use and target product profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- BioProcess Sciences, Pharma Services, Viral Vector Services, Thermo Fisher Scientific, Plainville, MA 02762, USA.
- BioProcess Sciences, Pharma Services, Viral Vector Services, Thermo Fisher Scientific, Plainville, MA 02762, USA. Electronic address: pouria.motevalian@thermofisher.com.
Zitieren
APA
Park, M. T., Verma, A., Froelich, C. A., & Motevalian, S. P. (2025). Process and quality considerations for recombinant adeno-associated virus manufacturing platforms. Trends in Biotechnology, 43(8), 1921-1937. https://doi.org/10.1016/j.tibtech.2025.02.016
Vancouver
Park MT, Verma A, Froelich CA, Motevalian SP. Process and quality considerations for recombinant adeno-associated virus manufacturing platforms. Trends in Biotechnology. 2025;43(8):1921-1937. doi:10.1016/j.tibtech.2025.02.016
BibTeX
@article{Park2025,
author = {Park, Min Tae and Verma, Amrisha and Froelich, Clifford A and Motevalian, Seyed Pouria},
title = {Process and quality considerations for recombinant adeno-associated virus manufacturing platforms},
journal = {Trends in Biotechnology},
year = {2025},
volume = {43},
number = {8},
pages = {1921--1937},
doi = {10.1016/j.tibtech.2025.02.016}
}
EUVIMED